Kornimate/medical-research-clean huggingface dataset:
effect of motivational interviewing on sleep hygiene, sleep quality and quality of life

Conditions: Sleep Hygiene

Summary: * sleep hygiene education and motivational interviewing have an effect on increasing sleep hygiene in individuals undergoing hemodialysis treatment * sleep hygiene education and motivational interviewing have an effect on increasing sleep quality in individuals undergoing hemodialysis treatment * sleep hygiene education and motivational interviewing have an effect on increasing quality of life in individuals undergoing hemodialysis treatment

after the pre-tests are applied to the patients in the intervention group, face-to-face sleep hygiene training will be given, and then 4 sessions of motivational interviews will be held within 6 weeks. the sessions will be conducted online with each patient individually. the post-test will be applied 10 weeks after the pre-test.

Eligibility criteria:
inclusion criteria: * patients undergoing hemodialysis at akdeniz university hospital * having been on a routine hemodialysis program for at least 3 months, * having a score of ≥ 26 according to the sleep hygiene index * having dialysis adequacy (kt/v and urr values within normal range) * being an individual aged 18 and over * not having any written or verbal communication barriers * being able to use technological devices such as computers, tablets, mobile phones to conduct online motivational interviews * being willing to participate in online motivational interviews exclusion criteria: * having a health problem that affects sleep patterns (sleep apnea, surgical operation (temporary hemodialysis catheter insertion and other surgical procedures, depression, anxiety disorder, etc.) * having previously attended any motivational interview session for sleep hygiene

Keywords: nursing hemodialysis motivational interviewing sleep hygiene sleep quality quality of life
temozolomide plus anti-angiogenesis drugs and radiotherapy as a treatment for glioblastoma

Conditions: Glioblastoma

Summary: temozolomide (tmz) is an oral chemotherapy drug. it is an alkylating agent used as a first-line treatment for glioblastoma. this methylation damages the dna and triggers the death of tumor cells. according to the results of several clinical studies, tmz synchronous plus radiotherapy and subsequent as adjuvant therapy can significantly improve the survival rate of newly diagnosed glioblastoma patients.

glioma is the highest incidence of the central nervous system tumor. surgical treatment is one of the most important therapeutic methods in patients with glioblastoma. but since malignant glioma is a highly invasive tumor, the rate of surgery failure is . so the postoperative therapy shall be accompanied by radiotherapy. since 1998, the clinical application of temozolomide(tmz) has brought hope for malignant glioma patients with its definite curative effect. according to the results of several clinical studies, tmz synchronous plus radiotherapy and subsequent as adjuvant therapy can significantly improve the survival rate of newly diagnosed gbm patients and break the survival limit of malignant glioma patients. besides, antiangiogenic therapy is also a choice for the treatment of glioblastoma patients. vascular endothelial growth factor receptors (vegfrs) inhibitors block the new formation around the tumor and cut down the supply of oxygen, nutrients and metabolic waste, so that the tumor is hard to proliferate and metastases.

Eligibility criteria:
search criteria: 1. subjects received anti-angiogenesis drugs simultaneous accompanied with radio-and chemotherapy in fuzhou zongyuan since october, 2017; 2. age: 18-70 years; 3. the first surgical pathology was diagnosed as glioblastoma, who grade iii or iv; 4. patients who have previously received no more than one surgical treatment; 5. ecog performance status: 0-2; 6. survival expectation≥3 months.

Keywords: temozolomide apatinib radiotherapy
inappropriate sinus tachycardia registry

Conditions: Inappropriate Sinus Tachycardia; Postural Tachycardia Syndrome

Summary: the primary objective of this registry is to capture real-world safety and performance data on atricure devices used to ablate cardiac tissue when treating inappropriate sinus tachycardia (ist) or postural tachycardia syndrome (pots). this is a retrospective and prospective, multicenter, us/ous, observational data registry.


Eligibility criteria:
inclusion criteria: 1. subject is scheduled to undergo or has undergone a procedure to treat ist or pots using one or more atricure devices. 2. subject is willing to provide written informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this registry) or authorization per institution and geographical requirements exclusion criteria: 1. subject is enrolled in a concurrent study that may impact treatment outcome of ist or pots. 2. subject with exclusion criteria required by fda or local governance

Keywords: inappropriate sinus tachycardia postural tachycardia syndrome; sinus node sparing hybrid procedure
a new intelligent stocking for quantification of edema in the lower limbs

Conditions: Edema Leg

Summary: the purpose of the study is to evaluate a prototype of an intelligent stocking (edema stocking device \[esd\]), consisting of two stretch sensitive sensors, as a new method for continuously lower leg volume monitoring. the study is a scientific evaluation of the esd compared with water displacement volumetry and tape measure.

background: balance of body fluids is strictly regulated within a narrow range and is controlled by water movement between the interstitial compartment and the capillaries. an unnatural balance between the two compartments can be seen in several diseases, leading to a net filtration out of the vascular space, resulting in the formation of edema. monitoring of edema formation represents a unique way of evaluating the degree of the underlying disease and effect of treatment. numerous different methods can be used to quantify leg volume. however, no current method provides continuous quantitative assessment. the feasibility of continuous lower leg measuring using an intelligent stocking was hypothesized. the aim of the study was to evaluate the edema stocking device (esd) as a tool for continuous quantification of edema compared with water displacement volumetry (wdv) and tape measure. materials and methods: study design: non-randomized equivalence study. experimental comparison study of new method compared to golden standard.

Eligibility criteria:
inclusion criteria: * edema of the lower legs. * between 20-18 years. * identified at department of gynaecology and obstetrics, aarhus university hospital, denmark. exclusion criteria: * length of lower leg of more than 34,0 cm (measured from floor to knee).

Keywords: lower leg edema equivalence study leg volume
congenital athymia patient registry

Conditions: Complete DiGeorge Anomaly; Complete DiGeorge Syndrome; Congenital Athymia

Summary: this congenital athymia patient registry is an observational exposure-based registry study. it uses a prospective cohort design to follow patients who have been treated with rethymic. clinical studies conducted with investigational rethymic showed that treatment can result in immune reconstitution and prolong life. this treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (aesi).

this congenital athymia patient registry is an observational exposure-based registry study. it uses a prospective cohort design to follow patients who have been treated with rethymic. clinical studies conducted with investigational rethymic showed that treatment can result in immune reconstitution and prolong life. this treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (aesi). currently, there is a single site where patients are being treated with rethymic. the investigator will be responsible for recruiting patients who have recently had (i.e., within the past 60 days) or are scheduled to have this treatment within 30 days and obtaining signed informed consent (and assent as applicable). the investigator will collect baseline medical history and clinical data information for each enrolled subject. the start of follow-up (day 1) begins on the day following treatment surgery. clinical data and flow cytometry test results (when conducted) will be abstracted from the medical records by clinical staff at baseline and during follow-up at predefined intervals.

Eligibility criteria:
inclusion criteria: * pediatric patients diagnosed with congenital athymia: * who are scheduled for implantation with rethymic within the next 30 days, or who were treated with rethymic within the previous 60 days. * who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian. exclusion criteria: * written informed consent cannot be obtained.

Keywords: congenital athymia
effect of intense pulse light (ipl) treatment on tear film osmolarity

Conditions: Dry Eye

Summary: evaluate changes in tear film osmolarity and other ded signs/symptoms following treatment with ipl.

prospective study design among subjects with mgd and qualifying for ipl therapy. study testing done at baseline visit when subjects are scheduled for ipl therapy. measurements will be made on day 15 (prior to second ipl sitting), day 45 (prior to third ipl setting), day 75 (fourth ipl setting) and day 105 as needed (30 days after ipl setting 4). subjects willing to come for follow up visits as scheduled and may not have instilled any artificial tears 2 hours prior to study measurements. no history of ocular infection or corneal degeneration/dystrophy no history of corneal refractive surgery and/or change in ocular medications in the last 2 months

Eligibility criteria:
inclusion criteria: * dry eye * mgd exclusion criteria: * no history of ocular infection or corneal degeneration/dystrophy * no history of corneal refractive surgery * no change in ocular medications in the last 2 months
prehabilitation in geriatric patients with colorectal neoplasia

Conditions: Colo-rectal Cancer

Summary: this an interventional, non-pharmacologic study. prehabilitation is a multidisciplinary preoperative intervention aimed at preventing or reducing functional decline related to surgery and improving perioperative outcomes. the current study is aimed at standardizing a prehabilitation pathway, evaluating its feasibility within the ausl romagna in collaboration with the prime centre and the multiple professions that populate the two institutes in the spirit of confirming the beneficial effect of an integrated prehabilitation programme on surgical outcomes. patients will follow an intensive prehabilitation course before surgery: * colon cancer patients will do 4 weeks of prehabilitation before surgery. * rectal cancer patients will do 12 weeks of prehabilitation after neoadjuvant therapy and before surgery. the prehabilitation course is structured around the following aspects: * frailty assessment and identification of optimisation fields * optimisation of modifiable factors (anaemia, polypharmacotherapy, smoking, alcoholism, diabetes) * assessment by an integrative medicine specialist * nutritional pre-qualification * cardiovascular, respiratory, motor prehabilitation * emotional and psychological prehabilitation


Eligibility criteria:
inclusion criteria: 1. the participant (or legally acceptable representative if applicable) provides written informed consent for the trial. 2. male/female participants who are at least 70 years of age on the day of signing informed consent. 3. patients with confirmed diagnosis of colorectal cancer awaiting major surgery. exclusion criteria: 1. clinical need for emergency intervention. 2. severe cognitive impairment (mmse\<20\*) 3. severe dependency (adl\<3) 4. stage iv colorectal neoplasia

Keywords: prehabilitation
stress biomarkers leading to professional burnout among people involved in a mobile intensive care unit during the covid-19 pandemic

Conditions: Occupational Stress

Summary: this study is aiming at investigating whether professional burnout in people involved in the mobile intensive care unit (in french: element mobile de réanimation, emr) in mulhouse (france) can be predicted upstream by a low mindfulness level (as a protective factor) or by a dysregulation of stress pathways with a high level of perceived stress towards an emotional event (psychological index of allostatic load), i.e. an early and silent dysfunctional physiological response (measured by the electrophysiological and biological measurements of allostasis load and parasympathetic brake). it is part of a global approach aiming at identifying levers to prevent the allostatic load of occupational stress related to large-scale health crises.


Eligibility criteria:
inclusion criteria: * volunteer staff member of the mulhouse mobile intensive care unit (in french: elément mobile de réanimation, emr), including military reservists. exclusion criteria: * pregnant or breastfeeding woman, * person deprived of liberty by a judicial or administrative decision, * person subject to a legal protection measure or unable of giving consent * intercurrent pathology with inability to work * history of psychiatric disorder or cardiac pathology
trefoil peptides in lung diseases

Conditions: Chronic Obstructive Pulmonary Disease; Asthma

Summary: the study focuses on trefoil family factor (tff) peptides in sputum in lung diseases. the investigators hypothesize that tff peptides are upregulated in lung diseases characterized by mucus hypersecretion.


Eligibility criteria:
inclusion criteria: * age 18 years or older * informed consent exclusion criteria: * upper and lower airway infection 2 weeks prior to visit 1

Keywords: copd
laparoscopic vs open hernia mesh repair for inguinal hernia

Conditions: Hernia, Inguinal

Summary: this study will determine whether laparoscopic and open hernia repair have the same recurrence and complication rates in the under 60yr old age group. the overall financial costs of each repair will also be compared.

study population is waitemata health (auckland new zealand) patients presenting to clinic with unilateral primary inguinal hernia aged less than 60 years, fit for surgery and able to consent for the study. randomized to open mesh repair or laparoscopic preperitoneal mesh repair. two surgeons (dr rodgers and dr hammodat) using a standardized technique. conversion rates from lap to open will be recorded. phone assessment postop day 1, 1 week and at 6 months. clinic assessment at 4 weeks, 1 year and 2 years. primary outcome is hernia recurrence which will be assessed by a research nurse independent of surgeon at each clinic appointment. assessment to also include assessment of ongoing symptoms such as pain/discomfort, sensory disturbance, and sexual dysfunction. quality of life assessment (sf 36 questionnaire) preoperatively and at each assessment. pain assessment 4hrs postop and at all other assessments by score 0-10 and measurement of pain relief. cost analysis to include the following parameters: theatre equipment costs, theatre time, drug use, hospital stay, time to return to work, time to return to normal activities. interim analysis at 2 years of followup by independent health and safety committee. final analysis at 4 years of followup.

Eligibility criteria:
inclusion criteria: * male \<60yrs with primary inguinal hernia exclusion criteria: * recurrent hernia * bilateral hernia * non-reducible/obstructed hernia * previous lower abdominal surgery/radiotherapy

Keywords: hernia inguinal groin laparoscopic open abdominal wall
virosensor -based real-time diagnosis of enterovirus 71 and influenza virus

Conditions: Enterovirus 71 and Influenza Virus

Summary: to develop a real-time diagnostic technique with virosensor for enterovirus 71 and influenza virus detection, the investigators conduct a prospective clinical study. in comparison with results from direct sequencing of enterovirus 71 and influenza virus, the investigators evaluate the performance of virosensor , including reproducibility, sensitivity, specificity, and cross-reaction. the potential factors which may interfere with the results would be investigated. with such technique, the investigators hope to make early diagnosis and give enterovirus 71 and influenza virus patients early treatment to reduce the complications and case-fatality rate.

1. sample acquirement： at national taiwan university hospital in taiwan, we will enroll patients who have influenza-like illness or enterovirus infection . we will take three throat swabs for each patient: one for viral isolation, one for rt-pcr and the last for the virosensor - based real-time diagnosis. 2. virosensor diagnosis： virosensor (structural chip-based optosensing virus probing system), which is for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-enterovirus 71-virus) and its influenza virus antigen (or enterovirus 71 antigen) present in patients'and normal samples. 3. gold standard： viral isolation and rt-pcr

Eligibility criteria:
inclusion criteria: * the patients with confirmed or suspected infection. * the healthy person without disease. exclusion criteria: * none

Keywords: enterovirus 71 and influenza virus
arq 197 plus erlotinib in patient with locally advanced or metastatic egfr mutation-positive non-small-cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: the primary objective of this study is to examine if the combination regimen of arq 197 with erlotinib is active in subjects with locally advanced or metastatic nsclc with activating mutation egfr who progressed on egfr-tki monotherapy.


Eligibility criteria:
key inclusion criteria: * histologically or cytologically confirmed surgically unresectable locally advanced or metastatic (stage iiib/iv) nsclc with egfr activating mutation. * measurable disease and documented disease progression following the first and immediate egfr-tki monotherapy. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate organ function key exclusion criteria: * prior therapy with a c-met inhibitor. * any systemic anti-tumor treatment for nsclc within 7 days prior to randomization. * major surgical procedure within 4 weeks prior to randomization * known symptomatic brain metastases.

Keywords: nsclc c-met egfr mutation-positive gefitinib erlotinib egfr-tki resistance
ct-95 in advanced cancers associated with mesothelin expression

Conditions: Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced; Malignant Peritoneal Mesothelioma, Advanced; Pancreatic Adenocarcinoma Advanced or Metastatic; Lung Adenocarcinoma Metastatic; Cholangiocarcinoma Advanced; Cholangiocarcinoma Non-resectable; Mesothelin-expressing Advanced Cancers; Mesothelin-positive Advanced Malignant Solid Tumors; Colorectal Cancer

Summary: this is a phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of ct-95 (study drug), a humanized t cell engaging bispecific antibody targeting mesothelin, in subjects with advanced solid tumors associated with mesothelin expression.

the phase 1a dose escalation portion of the trial will enroll subjects in one of approximately 8 dose escalation cohorts to assess the safety and tolerability of ct-95, as well as determine the maximum tolerated dose (mtd) or other recommended dose(s) for expansion (rde\[s\]) for further study in 2 dose optimization cohorts. subjects will receive ct-95 as a single agent administered once weekly (qw) intravenously (iv) over a 4-week cycle. the phase 1b dose expansion portion will evaluate ct-95 in indication-specific expansion cohorts

Eligibility criteria:
inclusion criteria: * ecog 0 or 1 * subjects with evaluable disease per recist 1.1 or mrecist * subjects with adequate organ function. * subjects with advanced cancers associated with mesothelin expression exclusion criteria: * uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study. * prior treatment with msln-targeted cd3 or chimeric antigen receptor t cell (car-t) therapy * concurrent participation in another investigational clinical trial. * evidence of leptomeningeal disease

Keywords: phase 1 dose escalation study ct-95 advanced, recurrent cancers unresectable, metastatic cancers cancers associated with mesothelin expression
comparison of piezosurgery and conventional rotary instruments in impacted third molar surgery

Conditions: Impacted Third Molar Tooth

Summary: the purpose is to compare the effects of piezosurgery and conventional rotary instruments on postoperative pain, swelling, trismus and patients' comfort after mandibular third molar surgery.

the investigators plan a prospective and split mouth study. thirty patients will be randomly selected. inclusion criteria were being older than 18 of age, having asymptomatic bilateral mesioangular impacted mandibular third molar (pell and gregory class ii, position b) fully covered with mucosa and bone, and being otherwise medically healthy. one side of the patients will be randomly selected and labeled as "experimental group". in experimental group, impacted third molar will be extracted using piezosurgery. the other side will be accepted as "control group". in the control group, impacted third molar will be extracted using conventional rotary instruments.there will at least one month between two surgeries. the investigators will compare postoperative pain, swelling, trismus and patients' comfort.

Eligibility criteria:
inclusion criteria: * inclusion criteria were being older than 18 of age, having asymptomatic bilateral mesioangular impacted mandibular third molar (pell and gregory class ii, position b) fully covered with mucosa and bone, and being otherwise medically healthy. exclusion criteria: * exclusion criteria were as follows: alcohol abuse, smoking, pregnancy, and presence of acute severe periodontitis.

Keywords: trismus piezosurgery pain swelling
effects of novel combinations of tolterodine/pilocarpine on pharmacokinetics (pk) and pharmacodynamics (pd) of tolterodine in healthy subjects

Conditions: Incontinence

Summary: thvd-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

because of the limitations of taking two medications separated by a period of time to minimise these adverse events, two novel formulations were developed to improve compliance and ease of administration. this study will evaluate these formulations in terms of their pharmacokinetic profiles and effects on ssf. in addition, the effects of this combination and its entities on urine frequency and safety/tolerability will be assessed.

Eligibility criteria:
inclusion criteria: * healthy males, 18 - 45 years of age. * bmi 20-30 m2. exclusion criteria: * subjects who have a history of sensitivity to antimuscarinic or muscarinic agents or related derivatives. * clinically significant ecg, vital signs and clinical laboratory indices.

Keywords: tolterodine over active bladder (oab) incontinence